2025-11-24 - Analysis Report
Okay, here's a comprehensive analysis of Natera Inc (NTRA) based on the data provided.

**0) Overview:**

Here's the report in English, starting with simple numbers and then analysis:

**1) Return Rate Comparison (NTRA vs. S&P 500):**

*   **NTRA Cumulative Return:** 137.41%
*   **VOO (S&P 500) Cumulative Return:** 95.46%
*   **Divergence:** 42.0
*   **Relative Divergence:** 49.7

*Natera Inc. (NTRA) is a genetic testing company focused on women's health, oncology, and organ health.*

**Analysis:**

NTRA has significantly outperformed the S&P 500 in cumulative return (137.41% vs 95.46%). The divergence is currently 42.0, with a relative divergence of 49.7, indicating that the current divergence is slightly below the midpoint of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -10.0% | 70.1% | -34.0% | -0.0 | 1.2 |
| 2016-2018  | 22.0% | 80.0% | 6.0% | 0.0 | 1.9 |
| 2017-2019  | 50.0% | 80.0% | 28.0% | 1.1 | 4.7 |
| 2018-2020  | 186.0% | 80.5% | 163.0% | 1.2 | 13.7 |
| 2019-2021  | 96.0% | 80.5% | 49.0% | 1.6 | 12.9 |
| 2020-2022  | -77.0% | 80.5% | -76.0% | 0.1 | 5.5 |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1 | 8.7 |
| 2022-2024  | 8.0% | 76.6% | -13.0% | -1.2 | 21.9 |
| 2023-2025  | 164.0% | 76.6% | 105.0% | 0.1 | 31.8 |

*   **CAGR:** Varies significantly, with periods of strong growth (e.g., 186% in 2018-2020) and severe decline (e.g., -194% in 2021-2023). This highlights the stock's volatility.
*   **MDD (Maximum Drawdown):**  Consistently high, around 70-80%, indicating substantial risk and price fluctuations.
*   **Alpha:** Wide fluctuations, mirroring the CAGR. Positive alpha suggests outperformance relative to the market, while negative alpha indicates underperformance.
*   **Beta:** Generally around 1 or slightly above/below, suggesting that NTRA's volatility is roughly in line with or slightly more/less than the market. More recently, beta has fluctuated and is even negative on occasion.
*   **Cap(B) - Capitalization (Billions):** NTRA's market capitalization has grown over time, peaking in the 2023-2025 period.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 230.63
*   **Previous Close:** 225.55
*   **Change:** 2.25
*   **5-day SMA:** 218.844
*   **20-day SMA:** 204.343
*   **60-day SMA:** 183.4015

**Analysis:**

The stock is trading above all its short-term and medium-term moving averages, suggesting a bullish trend. The closing price is higher than previous close, indicating positive momentum.

**3) RSI, PPO, Divergence Change, and Expected Return:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 80.60 (Overbought)
*   **PPO:** 0.8187
*   **Hybrid Signal:** Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) relative divergence change:** 11.7 (+) indicating short-term rise.
*   **Expected Return (%):** -48.0 (Long-term underperformance compared to S&P 500)

**Analysis:**

*   The RSI of 80.60 suggests the stock is currently overbought, potentially indicating a short-term correction.
*   The PPO is positive, confirming upward price momentum.
*   The Hybrid Signal indicates a "Buy" recommendation, possibly driven by a shorter-term perspective.
*   The large price change reflects a strong rebound or sharp decline, indicating a potentially volatile situation.
*   The negative Expected Return suggests analysts anticipate underperformance relative to the S&P 500 over the next 2 years.

**4) Recent News & Significant Events:**

*   **[2025-11-23]** Natera (NTRA): Evaluating Valuation After Q3 Growth, Analyst Upgrades, and OncoEMR Integration.
*   **[2025-11-21]** Why NTRA stock appeals to dividend seekers.
*   **[2025-09-24]** Why Natera (NTRA) Stock Is Down Today.
*   **[2025-11-19]** Natera (NASDAQ: NTRA) Volunteers Top 28,500 Hours, Surpassing 2025 Service Goal.
*   **[2025-11-18]** New Analyst Forecast: $NTRA Given $280.0 Price Target.
*   **[2025-11-20]** Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3.

**Analysis:**

The news headlines present a mixed picture. There's positive news regarding Q3 growth, analyst upgrades, Immuno-Oncology stocks, and a new price target of $280. However, there's also news about a stock price decrease on a specific date, suggesting potential volatility.

**4-2) Analyst Opinions:**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19
*   **Target Price:** Avg: 234.16 / High: 280.00 / Low: 186.00

**Analysis:**

Despite the negative expected return, the analyst consensus is "Strong Buy", suggesting that analysts believe the stock is currently undervalued or has strong growth potential despite risks. The average target price is slightly above the current price.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.5  | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

**Analysis:**

The company is consistently reporting negative Earnings Per Share (EPS), indicating it's not currently profitable. However, revenue is generally trending upward.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $0.59B    | 64.91%        |
| 2025-06-30 | $0.55B    | 63.41%        |
| 2025-03-31 | $0.50B    | 63.12%        |
| 2024-12-31 | $0.48B    | 62.94%        |
| 2024-09-30 | $0.44B    | 61.79%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-09-30 | $1.25B    | -6.99%   |
| 2025-06-30 | $1.25B    | -8.10%   |
| 2025-03-31 | $1.24B    | -5.40%   |
| 2024-12-31 | $1.20B    | -4.50%   |
| 2024-09-30 | $0.88B    | -3.60%   |

**Analysis:**

*   **Revenue:** Consistently increasing, demonstrating top-line growth.
*   **Profit Margin:** High profit margins, however, this does not translate into profits as the company has negative EPS and negative ROE (likely due to high operational costs and R&D).
*   **Equity:** Stable and increasing.
*   **ROE (Return on Equity):** Negative, reflecting the lack of profitability.

**7) Comprehensive Analysis (Summary):**

Natera Inc. (NTRA) presents a mixed investment profile:

*   **Strengths:**
    *   Significant outperformance relative to the S&P 500 in the past.
    *   Strong revenue growth and high profit margins.
    *   "Strong Buy" analyst consensus and positive price targets.
    *   Positive short-term momentum as indicated by price movements and divergence change.
*   **Weaknesses:**
    *   High historical volatility (high MDD).
    *   Negative EPS and ROE, indicating a lack of profitability.
    *   Overbought RSI, potentially indicating a short-term correction.
    *   Negative expected return relative to the S&P 500 in the long term (2+ years).

**Conclusion:**

NTRA appears to be a high-risk, high-reward investment. The company has demonstrated strong growth potential and has captured market attention, but it struggles with profitability and experiences significant price volatility.  While analysts are generally positive, the negative expected return suggests caution for long-term investors. The recent surge in stock price suggests short term gain.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.